First and only steerable delivery system designed to help seal the left atrial appendage (LAA) in people with atrial fibrillation who are at an increased risk of stroke Now available in the U.S., ...

The US Food and Administration (FDA) has approved the Amplatzer Amulet left atrial appendage occluder (Abbott) to treat people with nonvalvular atrial fibrillation who are at increased risk for stroke ...

A head-to-head, randomized study of the two leading heart implants worldwide for reducing the risk of stroke among people with an irregular pulse found there was little difference between their safety ...

The Amplatzer Amulet (Abbott) and first-generation Watchman 2.5 (Boston Scientific) devices provide relatively comparable results out to 3 years after left atrial appendage occlusion (LAAO), longer ...

Boston Scientific and Abbott this week both put forward separate studies supporting their respective implants for sealing off the heart’s left atrial appendage—the pocket within the cardiac muscle ...

New results presented at Cardiovascular Research Technologies (CRT) 2023 demonstrate the safety of Navitor™ TAVI system and its effectiveness in minimizing blood leakage around the valve implant ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. BOSTON — At 3 years, the Amplatzer Amulet device ...

Boston Scientific Corp. and Abbott Laboratories continue to parry over clinical trials comparing the latter’s Amplatzer Amulet with Boston Scientific’s Watchman in sealing the heart’s left atrial ...

Five late-breaking presentations at TCT 2022 highlight the impact of Abbott's structural heart devices to repair or replace heart valves and close openings in the heart New data reinforce the safety ...

Data presented at EuroPCR 2022 reinforce the impact of Abbott's minimally invasive heart devices on patient outcomes and quality of life Findings demonstrate TriClip™ transcatheter edge-to-edge (TEER) ...